title: Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B.
abstract: The emergence of new and more potent treatment options has markedly changed the treatment landscape of chronic hepatitis B. Both peginterferon and nucleos(t)ide analogues have considerable advantages and limitations, and current treatment guidelines refrain from clearly suggesting a first-line treatment option. Peginterferon offers the advantage of higher sustained response rates in both hepatitis B early antigen (HBeAg)-positive and HBeAg-negative patients, at the price of considerable side effects and high costs. Nucleos(t)ide analogues offer easy daily oral dosing, and newly registered agents can maintain viral suppression for prolonged treatment duration. However, relapse is common after therapy discontinuation and extended therapy therefore often necessary. Prolonged treatment with nucleos(t)ide analogues may enhance chances of virologic and serologic response at the potential cost of the emergence of viral resistance and side effects. Baseline and on-treatment prediction of response may help select patients for peginterferon therapy and can aid individualized treatment decisions concerning therapy continuation or discontinuation.
authors.forename: Milan J
authors.initials: MJ
authors.lastname: Sonneveld
authors.forename: Harry L A
authors.initials: HL
authors.lastname: Janssen
references.citation: Antivir Ther. 2007;12(5):815-23
references.pmid: 17713165
references.citation: N Engl J Med. 2003 Feb 27;348(9):808-16
references.pmid: 12606735
references.citation: N Engl J Med. 2008 Oct 2;359(14):1486-500
references.pmid: 18832247
references.citation: N Engl J Med. 2008 Dec 4;359(23):2442-55
references.pmid: 19052126
references.citation: Lancet. 2009 Feb 14;373(9663):582-92
references.pmid: 19217993
references.citation: Hepatology. 2007 Feb;45(2):507-39
references.pmid: 17256718
references.citation: N Engl J Med. 2002 Jul 18;347(3):168-74
references.pmid: 12124405
references.citation: J Hepatol. 2000 Feb;32(2):300-6
references.pmid: 10707871
references.citation: N Engl J Med. 2006 Mar 9;354(10):1011-20
references.pmid: 16525138
references.citation: Hepatology. 2009 Apr;49(4):1151-7
references.pmid: 19115222
references.citation: N Engl J Med. 2007 Dec 20;357(25):2576-88
references.pmid: 18094378
references.citation: Hepatology. 2009 May;49(5 Suppl):S185-95
references.pmid: 19399802
references.citation: Hepatology. 2007 Aug;46(2):388-94
references.pmid: 17604363
references.citation: Gut. 2007 May;56(5):699-705
references.pmid: 17127704
references.citation: N Engl J Med. 2004 Sep 16;351(12):1206-17
references.pmid: 15371578
references.citation: Gastroenterology. 2007 Nov;133(5):1437-44
references.pmid: 17983800
references.citation: N Engl J Med. 2006 Mar 9;354(10):1001-10
references.pmid: 16525137
references.citation: J Viral Hepat. 2000 Sep;7(5):382-6
references.pmid: 10971827
references.citation: Am J Gastroenterol. 2007 Jan;102(1):96-104
references.pmid: 17266689
references.citation: N Engl J Med. 1999 Oct 21;341(17):1256-63
references.pmid: 10528035
references.citation: Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71
references.pmid: 15854180
references.citation: Hepatology. 2004 Mar;39(3):804-10
references.pmid: 14999700
references.citation: Gastroenterology. 2008 Aug;135(2):459-67
references.pmid: 18585385
references.citation: Hepatology. 2003 Apr;37(4):748-55
references.pmid: 12668966
references.citation: N Engl J Med. 1996 May 30;334(22):1422-7
references.pmid: 8618580
references.citation: Hepatology. 2009 May;49(5 Suppl):S96-S102
references.pmid: 19399800
references.citation: Hepatology. 2006 Feb;43(2 Suppl 1):S182-93
references.pmid: 16447260
references.citation: Lancet. 2005 Jan 8-14;365(9454):123-9
references.pmid: 15639293
references.citation: J Hepatol. 2009 Feb;50(2):289-95
references.pmid: 19070393
references.citation: Ann Intern Med. 2009 Jan 20;150(2):104-10
references.pmid: 19124811
references.citation: Gastroenterology. 2009 Dec;137(6):2002-9
references.pmid: 19737568
references.citation: N Engl J Med. 2004 Oct 7;351(15):1521-31
references.pmid: 15470215
references.citation: Kidney Int. 2004 Sep;66(3):1153-8
references.pmid: 15327411
references.citation: Hepatology. 2001 Jun;33(6):1527-32
references.pmid: 11391543
references.citation: Gastroenterology. 2009 Jun;136(7):2169-2179.e1-4
references.pmid: 19303414
references.citation: J Hepatol. 2008;48 Suppl 1:S2-19
references.pmid: 18304680
references.citation: Gastroenterology. 2004 Jun;126(7):1750-8
references.pmid: 15188170
references.citation: J Hepatol. 2008 Feb;48(2):335-52
references.pmid: 18096267
references.citation: J Hepatol. 2009 Feb;50(2):227-42
references.pmid: 19054588
references.citation: N Engl J Med. 2005 Jun 30;352(26):2682-95
references.pmid: 15987917
references.citation: J Hepatol. 2002 Nov;37(5):669-74
references.pmid: 12399235
references.citation: Am J Gastroenterol. 2007 Dec;102(12):2718-23
references.pmid: 17662102
references.citation: Hepatology. 2008 Feb;47(2):428-34
references.pmid: 18220290
references.citation: Hepatology. 2009 Apr;49(4):1141-50
references.pmid: 19338056
references.citation: Hepatology. 2006 Sep;44(3):721-7
references.pmid: 16941701
references.citation: Hepatology. 2009 May;49(5 Suppl):S112-21
references.pmid: 19399795
references.citation: Antiviral Res. 2003 Oct;60(2):87-9
references.pmid: 14638403
references.citation: Gut. 2005 Nov;54(11):1604-9
references.pmid: 15923670